Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDP1 Phase I in Advanced Solid Tumors
NCT04151810Phase 1Completed
- Sponsor
- Dragonboat Biopharmaceutical
- Start
- Dec 2019
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of cdp1 in solid tumor and penile squamous cell carcinoma (PSCC) (2 arms), sponsored by Dragonboat Biopharmaceutical. Primary endpoints: Dose Limiting Toxicities at 28 days and Recommended phase II dose at 6 months. Started Dec 2019; status: completed.
02
Drugs
cdp1
03
Conditions
solid tumorpenile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on NCT04151810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04151810.